The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Aegis Sciences Corporation, a leading provider of innovative toxicology and healthcare testing solutions, proudly announces ...

There are additional considerations that physicians need to consider when prescribing GLP-1s to patients with disabilities or ...

application for HBM9378/SKB378 (also known as WIN378), a fully human antibody targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic obstructive pulmonary disease (COPD). COPD is ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

Every year, 900,000 Americans are caught by surprise by the symptoms of a pulmonary embolism: a sudden shortness of breath, ...

A multimodal, digital community-based intervention was feasible and decreased illness-related distress in treating patients ...